Applicable groups and contraindications for pomalidomide

Pomalidomide is an oral immunomodulatory drug used primarily to treat multiple myeloma. This drug is particularly suitable for patients whose disease has not been controlled by at least two treatments, including lenalidomide and bortezomib. Pomalidomide regulates the immune system and inhibits the growth and spread of tumor cells, thereby prolonging patients' survival and improving their quality of life.

The applicable groups of pomalidomide mainly include:

Patients with relapsed or refractory multiple myeloma who are no longer sensitive to or resistant to traditional treatment options.

Patients with AIDS-related Kaposi's sarcoma or those who are resistant to antiretroviral therapy.

However, there are some clear contraindications and precautions for the use of pomalidomide:

Contraindicated in patients allergic to pomalidomide or any of its components.

Pomalidomide should be contraindicated in pregnant and breastfeeding women because the drug may cause serious birth defects or embryonic death. Women who plan to become pregnant should also avoid becoming pregnant during treatment and for a period of time after treatment, and take effective contraceptive measures.

Pomalidomide may cause serious hematological adverse reactions, such as neutropenia and thrombocytopenia, so patients' blood indicators need to be closely monitored during use.

Patients with risk factors such as deep vein thrombosis and pulmonary embolism need to be particularly careful when using pomalidomide and may need prophylactic medication.

Pomalidomide may also cause liver function abnormalities, so patients' liver function needs to be monitored regularly during use.

In short, pomalidomide is an effective drug for the treatment of multiple myeloma, but before use, the patient's condition and physical condition need to be carefully evaluated to ensure that the patient meets the medication conditions and follow the doctor's guidance for standardized medication.

xa0

Reference materials:https://www.drugs.com/mtm/pomalidomide.html